Cargando…

Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors

Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gara, Sudheer Kumar, Lack, Justin, Zhang, Lisa, Harris, Emerson, Cam, Margaret, Kebebew, Electron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178360/
https://www.ncbi.nlm.nih.gov/pubmed/30301885
http://dx.doi.org/10.1038/s41467-018-06366-z
_version_ 1783361953741144064
author Gara, Sudheer Kumar
Lack, Justin
Zhang, Lisa
Harris, Emerson
Cam, Margaret
Kebebew, Electron
author_facet Gara, Sudheer Kumar
Lack, Justin
Zhang, Lisa
Harris, Emerson
Cam, Margaret
Kebebew, Electron
author_sort Gara, Sudheer Kumar
collection PubMed
description Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37–57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs.
format Online
Article
Text
id pubmed-6178360
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61783602018-10-11 Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors Gara, Sudheer Kumar Lack, Justin Zhang, Lisa Harris, Emerson Cam, Margaret Kebebew, Electron Nat Commun Article Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37–57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs. Nature Publishing Group UK 2018-10-09 /pmc/articles/PMC6178360/ /pubmed/30301885 http://dx.doi.org/10.1038/s41467-018-06366-z Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Gara, Sudheer Kumar
Lack, Justin
Zhang, Lisa
Harris, Emerson
Cam, Margaret
Kebebew, Electron
Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
title Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
title_full Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
title_fullStr Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
title_full_unstemmed Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
title_short Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
title_sort metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178360/
https://www.ncbi.nlm.nih.gov/pubmed/30301885
http://dx.doi.org/10.1038/s41467-018-06366-z
work_keys_str_mv AT garasudheerkumar metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors
AT lackjustin metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors
AT zhanglisa metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors
AT harrisemerson metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors
AT cammargaret metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors
AT kebebewelectron metastaticadrenocorticalcarcinomadisplayshighermutationrateandtumorheterogeneitythanprimarytumors